Printer-friendly version
AlloSkin™ meshed human skin allograft (dermal and epidermal) is extensively tested, cleaned and cryopreserved for cell viability. Contains extracellular matrix proteins, glycosaminoglycans, cytokines and other natural vulnerary compounds that may interact to promote wound healing.
• Pliable, stretchable tissue allows graft contouring to wound topography
• Robust enough to suture or staple without tearing
• Meshing encourages fluid drainage from wound
AlloSkin™ can be used in a homologous fashion on any skin defect and is appropriate for use in traumatic and chronic wounds, including those where substructures such as bone, ligament, nerve or muscle are exposed.
Contraindicated for use when gross infection at the transplantation site is present.
As with all biological products, the tissue in AlloSkin™ has the potential to transmit infectious agents despite processing treatments, extensive donor screening, tissue selection and laboratory tests. See package insert for full listing.
Inherent uncertainty exists in medical and social histories and laboratory testing which may not detect known or unknown pathogens. Therefore, the following complications may occur with tissue transplantation: loss of integrity of transplanted tissue, immune response to transplanted tissue, transmission of known pathogens, and transmission or causation of disease of unknown etiology and characteristics. Adverse outcomes potentially attributable to AlloSkin™ must be promptly reported to the manufacturer. See package insert for full listing.
AlloSkin™ is cryopreserved and should be stored at or below -40°C. Shelf life of five years.
| Assigned HCPCS code | ● |
| Cryopreserved | ● |
| Sheet form | |
| Shelf life greater than 2 years | ● |
| Requires refrigeration | ● |
| Shelf life limited | |
| Indicated for acute wounds | |
| Indicated for chronic wounds | ● |
| Indicated for diabetic ulcers | ● |
| Indicated for pressure ulcers | ● |
| Indicated for surgical wounds | ● |
| Indicated for third-degree burns | ● |
| Indicated for venous ulcers | ● |
| Contact manufacturer for usage guidelines |
| Educational Material Available | ● |
| Free Samples/Trials Available | ● |
| Published Clinical Article Available | ● |
Acute Wounds
Burns
Chronic Wounds
Dehisced Wounds
Diabetic Foot
Granulating/Epithelializing Wounds
Non/Minimally Exudating Wounds
Pressure Ulcers
Surgical Wounds
Venous Ulcers
Ensure wound is adequately debrided and free of infection. Thaw in sterile isotonic solution for a minimum of 1-5 minutes. Affix AlloSkin™ graft per physician preference: can be stapled, sutured, glued, or tacked.
Inspect wound weekly, sooner if deemed necessary, to determine if AlloSkin™ is still in place or beginning to slough. Tissue generally sloughs in 7-14 days as wound bed granulation proceeds. Depending on wound assessment, clinician may leave graft in place. Additional applications are used if satisfactory closure has not been achieved with initial application. Typical wounds close with 1-3 applications.
Apply any combination of non-adherent sterile dressing over AlloSkin™.
Non-cytotoxic
AlloSource is a non-profit organization that offers more than 200 types of precise skin, bone, soft-tissue, and other allografts for use in an array of life-saving and life-enhancing medical procedures.